A Slough-based biopharmaceutical company celebrates 10 years since their acquisition
A Slough-based biopharmaceutical company celebrates 10 years since their acquisition by British technology firm Celltech.
UCB, whose head office is based on Bath Road, are a world leader in drug discovery and biopharmaceutical R&D. They specialise in small-molecule chemistry and leverage Celltech’s experience in antibody technology.
Dr Ismail Kola, executive vice-president and president of UCB NewMedicines, spoke about their plans for the future.
"Looking ahead, UCB plans to harness internal and external expertise in antibody and small molecules to develop highly effective and novel medicines for difficult to treat conditions in immunology and neurology," he said.
"In addition to these efforts, our breakthrough programs and technologies are paving the way for exciting new developments that are at the cutting-edge of scientific understanding”.
UCB and Celltech now employees over 8,500 people across 40 companies, and is set to keep making waves in their industry.
And of course, in Slough too.